Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Wells Fargo Maintains Overweight on Globus Medical, Raises Price Target to $79

Author: Benzinga Newsdesk | November 07, 2025 01:52pm
Wells Fargo analyst Vik Chopra maintains Globus Medical (NYSE:GMED) with a Overweight and raises the price target from $66 to $79.

Posted In: GMED

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist